SCHEMBL17897161

SCHEMBL17897161

c1cc2ccc3sccc3c2[nH]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.37
RIPK1 Q13546 1/20 0.37
AHR P35869 1/20 0.35
MAPT P10636 3/20 0.34
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
PIM3 Q86V86 1/20 0.33
KDM4E B2RXH2 2/20 0.33
CYP2A6 P11509 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29657656 0.98 TNF (0.36) TNFRIPK1AHRMAPTALDH1A1
SCHEMBL18897739 0.75 ADRA2A (0.48) AHRMAPTALDH1A1MEN1NPC1
SCHEMBL4418496 0.72 TYR (0.32) ADRA2AADRA2BKDM4ECYP2A6GAA
SCHEMBL4424091 0.72 DYRK1A (0.31) KDM4ECYP2A6
SCHEMBL30804604 0.72 CA12 (0.41) MAPTALDH1A1MEN1MAPK1KMT2A
SCHEMBL4419238 0.71 TNF (0.39) TNFRIPK1AHRMAPTALDH1A1
SCHEMBL2498909 0.69 KDM4E (0.45) MAPTALDH1A1HPGDADRA2AADRA2B
SCHEMBL29352476 0.69 KDM4E (0.45) MAPTALDH1A1HPGDADRA2AADRA2B
SCHEMBL29591462 0.69 TNF (0.54) TNFRIPK1AHRMEN1POLB
SCHEMBL1374474 0.69 TNF (0.54) TNFRIPK1AHRMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250073346-A1 PHARMACEUTICAL COMBINATIONS OXFORD BIOTHERAPEUTICS LTD (GB) 2025-03-06 US claimed
CN-119462761-A Thienoindole self-assembled small molecular compound and preparation method and application thereof 南京信息职业技术学院 2025-02-18 CN claimed
CN-119060095-A Self-assembled monomolecular film hole transport material based on fused thienoindole, and preparation method and application thereof 淮阴工学院 2024-12-03 CN claimed
EP-4433170-A1 PHARMACEUTICAL COMBINATIONS Oxford BioTherapeutics Ltd (GB) 2024-09-25 EP claimed
US-20240254238-A1 PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-CD205 ANTIBODY AND AN IMMUNE CHECKPOINT INHIBITOR OXFORD BIOTHERAPEUTICS LTD. (GB) 2024-08-01 US claimed
EP-4346882-A1 PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-CD205 ANTIBODY AND AN IMMUNE CHECKPOINT INHIBITOR Oxford BioTherapeutics Ltd (GB) 2024-04-10 EP claimed
WO-2023089314-A1 PHARMACEUTICAL COMBINATIONS OXFORD BIOTHERAPEUTICS LIMITED (GB) 2023-05-25 WO claimed
CN-111393452-B Asymmetric thieno-indole nuclear small molecule receptor material and preparation method thereof 湖南科技大学 2023-04-07 CN claimed
WO-2022248835-A1 PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-CD205 ANTIBODY AND AN IMMUNE CHECKPOINT INHIBITOR OXFORD BIOTHERAPEUTICS LTD (GB) 2022-12-01 WO claimed
US-20260069707-A1 COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES HALOZYME, INC. (US) 2026-03-12 US disclosed
US-20250375530-A1 ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES ALMAC DISCOVERY LTD (GB) 2025-12-11 US disclosed
US-20250331107-A1 ORGANIC FILM AND METHOD FOR PRODUCING SAME SHIKOKU CHEM (JP) 2025-10-23 US disclosed
US-20250263580-A1 METAL SURFACE TREATMENT LIQUID SHIKOKU CHEMICALS CORPORATION (JP) 2025-08-21 US disclosed
EP-4543489-A1 ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES Almac Discovery Limited (GB) 2025-04-30 EP disclosed
CN-114361180-A Semiconductor device and display device including the same 株式会社半导体能源研究所 2022-04-15 CN disclosed
US-20220073793-A1 ADHESIVE COMPOSITION, METHOD FOR PRODUCING SURFACE-TREATED METAL MEMBER, AND METHOD FOR PRODUCING METAL-RESIN COMPOSITE BODY MEC COMPANY LTD. (JP) 2022-03-10 US disclosed
CN-113026008-B Composition for forming coating film, method for producing surface-treated metal member, and method for producing metal-resin composite MEC股份有限公司 2022-02-25 CN disclosed
CN-114031754-A Thermally activated delayed fluorescence polymer and application thereof 南京邮电大学 2022-02-11 CN disclosed
US-20160197275-A1 EMITTER HAVING A CONDENSED RING SYSTEM MERCK PATENT GMBH (DE) 2016-07-07 US disclosed
US-20160197275-A1 EMITTER HAVING A CONDENSED RING SYSTEM MERCK PATENT GMBH (DE) 2016-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260069707-A1 COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES CD22, CD2, CD44 TNF 541/4885RIPK1 2804/4885AHR 529/4885
US-20250375530-A1 ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES EGFR, ROR1, ERBB2 TNF 3604/4885RIPK1 2559/4885AHR 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.